Q3 2024 Holdings
Filed 2024-11-14 | 68 holdings | $6.9B | 13F-HR | View on SEC ↗ · Holdings Table ↗
Sign in to see sub-manager breakdown
| Issuer | Class | CUSIP | Value ↓ | Shares | % Portfolio |
|---|---|---|---|---|---|
| Madrigal Pharmaceuticals Inc(MDGL) | COM | 558868105 | $423.1M | 1,993,687 | 6.1% |
| Axsome Therapeutics Inc(AXSM) | COM | 05464T104 | $376.5M | 4,189,557 | 5.4% |
| Avidity Biosciences Inc(RNA) | COM | 05370A108 | $373.5M | 8,132,870 | 5.4% |
| Argenx SE(ARGX) | SPONSORED ADR | 04016X101 | $354.8M | 654,430 | 5.1% |
| Natera Inc(NTRA) | COM | 632307104 | $329.2M | 2,593,323 | 4.8% |
| Rocket Pharmaceuticals Inc(RCKT) | COM | 77313F106 | $326.7M | 17,687,772 | 4.7% |
| PTC Therapeutics Inc(PTCT) | COM | 69366J200 | $274.3M | 7,393,127 | 4.0% |
| Dyne Therapeutics Inc(DYN) | COM | 26818M108 | $244.9M | 6,818,641 | 3.5% |
| Protagonist Therapeutics Inc(PTGX) | COM | 74366E102 | $244.2M | 5,426,112 | 3.5% |
| Bruker Corp(BRKR) | COM | 116794108 | $240.4M | 3,481,119 | 3.5% |
| Insmed Inc(INSM) | COM PAR $.01 | 457669307 | $238.9M | 3,272,008 | 3.5% |
| Acadia Pharmaceuticals Inc(ACAD) | COM | 004225108 | $210.8M | 13,707,506 | 3.1% |
| Merus N V | COM | N5749R100 | $208.3M | 4,169,393 | 3.0% |
| Geron Corp(GERN) | COM | 374163103 | $200.3M | 44,111,916 | 2.9% |
| Masimo Corp(MASI) | COM | 574795100 | $195.0M | 1,462,400 | 2.8% |
| Alkermes PLC(ALKS) | SHS | G01767105 | $186.2M | 6,654,033 | 2.7% |
| Akero Therapeutics Inc(AKRO) | COM | 00973Y108 | $169.8M | 5,919,435 | 2.5% |
| Apogee Therapeutics Inc(APGE) | COM | 03770N101 | $159.3M | 2,712,096 | 2.3% |
| Penumbra Inc(PEN) | COM | 70975L107 | $154.6M | 795,750 | 2.2% |
| Immunocore Hldgs PLC(IMCR) | ADS | 45258D105 | $151.6M | 4,869,798 | 2.2% |
| Cytokinetics Inc(CYTK) | COM NEW | 23282W605 | $143.7M | 2,721,158 | 2.1% |
| Stryker Corporation(SYK) | COM | 863667101 | $143.4M | 396,921 | 2.1% |
| Radnet Inc(RDNT) | COM | 750491102 | $125.5M | 1,808,604 | 1.8% |
| Establishment Labs Hldgs Inc(ESTA) | COM | G31249108 | $114.5M | 2,645,703 | 1.7% |
| Immatics N.v(IMTX) | SHS | N44445109 | $114.1M | 10,000,000 | 1.7% |
| Tarsus Pharmaceuticals Inc(TARS) | COM | 87650L103 | $112.2M | 3,412,486 | 1.6% |
| Ultragenyx Pharmaceutical in(RARE) | COM | 90400D108 | $109.3M | 1,968,002 | 1.6% |
| Spyre Therapeutics Inc(SYRE) | COM NEW | 00773J202 | $95.8M | 3,258,360 | 1.4% |
| Cargo Therapeutics Inc(CRGX) | COM | 14179K101 | $75.6M | 4,098,955 | 1.1% |
| Arvinas Inc(ARVN) | COM | 04335A105 | $68.5M | 2,782,329 | 1.0% |
| Stoke Therapeutics Inc(STOK) | COM | 86150R107 | $57.2M | 4,652,285 | 0.8% |
| 89Bio Inc(ETNBGBP) | COM | 282559103 | $54.6M | 7,378,548 | 0.8% |
| CG Oncology Inc(CGON) | COM | 156944100 | $50.7M | 1,344,074 | 0.7% |
| Glaukos Corp(GKOS) | COM | 377322102 | $50.3M | 386,291 | 0.7% |
| Urogen Pharma LTD(URGN) | COM | M96088105 | $48.1M | 3,787,347 | 0.7% |
| Neurogene Inc(NGNE) | COM | 64135M105 | $47.6M | 1,135,256 | 0.7% |
| Oruka Therapeutics Inc(ORKA) | COM | 687604108 | $45.4M | 1,850,648 | 0.7% |
| Orchestra Biomed Hldgs Inc(OBIO) | COM | 68572M106 | $42.2M | 8,206,159 | 0.6% |
| Sage Therapeutics Inc(SG7) | COM | 78667J108 | $40.4M | 5,591,700 | 0.6% |
| Taysha Gene Therapies Inc(TSHA) | COM SHS | 877619106 | $30.0M | 14,946,420 | 0.4% |
| Cullinan Therapeutics Inc(CGEM) | COM | 230031106 | $28.6M | 1,705,960 | 0.4% |
| Tempus AI Inc(TEM) | CL A | 88023B103 | $22.6M | 400,000 | 0.3% |
| GH Research PLC(GHRS) | ORDINARY SHARES | G3855L106 | $22.3M | 3,327,129 | 0.3% |
| Lenz Therapeutics Inc(LENZ) | COM | 52635N103 | $20.5M | 863,389 | 0.3% |
| Essa Pharma Inc(EPIEUR) | COM NEW | 29668H708 | $19.8M | 3,261,496 | 0.3% |
| Tourmaline BIO Inc(TRML) | COM | 89157D105 | $19.1M | 741,656 | 0.3% |
| Dianthus Therapeutics Inc(DNTH) | COM | 252828108 | $18.3M | 666,667 | 0.3% |
| Roivant Sciences LTD(ROIV) | SHS | G76279101 | $16.8M | 1,454,273 | 0.2% |
| Bioage Labs Inc(BIOA) | COM | 09077V100 | $16.4M | 786,353 | 0.2% |
| Replimune Group Inc(REPL) | COM | 76029N106 | $12.4M | 1,133,787 | 0.2% |